sever
acut
respiratori
syndrom
sar
seriou
infecti
diseas
caus
sar
coronaviru
assess
potenti
primeboost
vaccin
protocol
base
nucleocapsid
nc
protein
coadminist
deriv
mucos
adjuv
express
modifi
vaccinia
viru
ankara
mvanc
stimul
humor
cellular
immun
respons
system
mucos
level
obtain
result
demonstr
strong
immun
respons
elicit
system
mucos
level
follow
heterolog
primeboost
vaccin
protocol
consist
prime
nc
protein
addmix
intranas
rout
boost
mvanc
intramuscular
rout
sever
acut
respiratori
syndrom
sar
emerg
infecti
diseas
human
caus
sar
coronaviru
sarscov
character
high
degre
transmiss
mortal
mode
sarscov
transmiss
includ
shed
viru
respiratori
tract
via
droplet
close
contact
fomit
incub
period
sar
rang
day
mean
incub
time
day
infect
peopl
develop
influenzalik
symptom
lung
target
organ
eg
highgrad
fever
chill
myalgia
headach
dyspnea
result
mortal
rate
especi
older
patient
evidenc
sporad
case
report
late
http
wwwwprowhointsarsdocspressreleasespr
asp
http
enindex
html
sarscov
still
remain
constant
threat
epidem
outbreak
therefor
urgent
need
develop
effect
vaccin
abl
contain
futur
sar
outbreak
far
sar
viru
seem
remark
invari
genom
sequenc
isol
sar
patient
singapor
toronto
china
hong
kong
reveal
chang
basic
may
give
chanc
develop
vaccin
worldwid
use
order
gener
vaccin
provid
protect
immun
sarscov
pandem
potenti
would
critic
promot
elicit
long
last
immun
high
percentag
vaccin
individu
sever
vaccin
approach
test
experiment
anim
model
howev
vaccin
avail
agent
yet
human
use
current
three
main
strategi
pursu
order
develop
antisar
vaccin
name
inactiv
virusbas
spike
protein
base
nucleocapsid
nc
base
vaccin
inactiv
vaccin
immun
sproteinbas
vaccin
seem
stimul
high
titer
neutral
antibodi
well
cellular
immun
howev
abl
provid
limit
degre
protect
infect
interestingli
experi
vaccin
infecti
bronchiti
viru
chicken
ibv
success
wide
use
vaccin
coronavirus
indic
protect
infect
provid
inactiv
live
attenu
vaccin
via
neutral
antibodi
short
live
declin
appar
week
singl
applic
vaccin
result
protect
less
chicken
similarli
immun
ibv
larg
protein
induc
viru
neutral
antibodi
percentag
protect
chicken
hand
initi
immun
studi
ibv
nc
protein
appli
protein
dna
vaccin
also
induc
protect
immun
obvious
provid
tcell
possibl
local
antibodi
similar
observ
report
also
coronaviru
infect
anim
even
basi
protect
coronaviru
infect
well
understood
could
basi
altern
vaccin
develop
sarscov
use
nc
protein
promot
protect
infect
diseas
lung
tissu
infect
sarscov
would
essenti
stimul
also
elicit
robust
mucos
immun
respons
entri
site
therefor
present
work
evalu
differ
ncbase
vaccin
protocol
abil
stimul
humor
cellular
immun
respons
system
mucos
level
end
mice
immun
homolog
heterolog
primeboost
vaccin
regimen
base
recombin
nc
protein
coadminist
mucos
adjuv
express
highli
attenu
modifi
vaccinia
ankara
mva
viru
obtain
result
demonstr
strong
immun
respons
elicit
system
mucos
level
follow
heterolog
primeboost
vaccin
protocol
consist
prime
nc
protein
addmix
deriv
intranas
rout
boost
mvanc
intramuscular
rout
data
suggest
primeboost
approach
might
use
confer
protect
sar
gener
mvanc
construct
sequenc
sarsnc
gene
clone
smai
site
mva
transfer
plasmid
transfectioninfect
bhk
cell
mva
clonal
pure
mvasarsnc
select
consecut
round
plaqu
purif
cef
subsequ
high
titer
vaccin
stock
prepar
infect
cef
cultur
purif
sucros
cushion
histag
sarscov
nc
protein
express
escherichia
coli
invitrogen
induct
larabinos
bacteri
cell
lyse
gdnhcl
mm
na
po
mm
nacl
ph
lysat
load
ninitrilotriacet
acid
affin
column
invitrogen
sever
wash
step
histag
protein
recov
elut
buffer
contain
urea
mm
na
po
mm
imidazol
ph
elut
protein
refold
dialysi
sodium
acet
ph
quantifi
bradford
assay
coomassi
protein
assay
reagent
pierc
bonn
germani
lp
content
protein
prepar
pgg
determin
hekblu
tm
lp
detect
kit
invivogen
san
diego
usa
balbc
mice
n
harlan
winkelmann
gmbh
borchen
germani
immun
intranas
intramuscular
rout
day
see
tabl
anim
receiv
pfu
mvanc
mva
alon
g
nc
protein
respect
immun
nc
protein
mucos
rout
vaccin
formul
contain
g
pegyl
synthet
deriv
agonist
macrophageactiv
lipopeptid
kda
mycoplasma
fermentan
mucos
adjuv
molecul
compos
doubl
fatti
acid
substitut
cystein
bound
via
carboxyl
group
monomethoxi
polyethylen
glycol
rest
result
conjug
solubl
water
biocompat
nonimmunogen
parenter
vaccin
nc
protein
perform
use
alum
adjuv
serum
sampl
collect
day
wherea
bronchoalveolar
lavag
spleen
cell
sampl
day
sera
test
ncspecif
igg
elisa
brief
nuncimmuno
maxisorp
assay
plate
nunc
roskild
denmark
coat
lwell
nc
gml
coat
buffer
bicarbon
ph
overnight
incub
c
plate
block
bovin
serum
albumin
bsa
phosphat
buffer
salin
pb
ph
h
c
serial
dilut
pool
sera
bsa
ad
lwell
plate
incub
h
c
four
wash
secondari
biotinyl
antibodi
ad
follow
h
incub
c
six
wash
lwell
peroxidas
conjug
streptavidin
pharmingen
ad
plate
incub
min
room
temperatur
final
six
wash
substrat
abt
azinobi
acid
citratephosph
buffer
contain
h
ad
plate
incub
min
room
temperatur
endpoint
titer
express
last
dilut
give
u
neg
control
igg
isotyp
present
serum
sampl
determin
elisa
previous
describ
use
secondari
antibodi
biotinconjug
rat
antimous
southern
biotechnolog
associ
birmingham
uk
amount
total
ncspecif
iga
present
bronchoalveolar
vagin
lavag
individu
mice
determin
elisa
previous
describ
establish
iga
standard
curv
plate
coat
goat
antimous
iga
sigma
chemi
captur
antibodi
incub
serial
dilut
purifi
mous
iga
dianova
hamburg
germani
secondari
antibodi
biotinyl
goat
antimous
iga
sigma
chemi
use
plate
develop
describ
compens
variat
effici
recoveri
secretori
antibodi
anim
result
normal
express
percentag
ncspecif
iga
respect
total
amount
iga
present
sampl
investig
tcell
prolifer
spleen
cell
isol
day
immun
pool
within
group
adjust
cellsml
complet
medium
rpmi
supplement
fetal
calf
serum
cell
seed
lwell
flatbottom
microtit
plate
nunc
incub
day
presenc
gml
nc
protein
respect
final
h
cultur
ci
h
thymidin
amersham
intern
freiburg
germani
ad
well
afterward
cell
harvest
paper
filter
filtermat
wallac
freiburg
germani
use
cell
harvest
inotech
wohlen
switzerland
amount
h
thymidin
incorpor
dna
prolifer
cell
determin
scintil
counter
wallac
microtrilux
determin
amount
secret
cell
murin
elispot
kit
bd
pharmingen
use
accord
manufactur
instruct
brief
flatbottom
plate
hydrophob
high
protein
bind
immobilonpmembran
coat
correspond
captur
antibodi
store
night
c
remov
unbound
captur
antibodi
plate
wash
unspecif
bind
site
satur
incub
block
solut
h
room
temperatur
rt
afterward
splenocyt
well
incub
c
atmospher
contain
co
h
h
absenc
presenc
nc
protein
gml
neg
control
cell
cultur
rpmi
complet
medium
without
stimul
stimul
cellswel
cona
posit
control
dilut
rpmi
final
concentr
gml
incub
plate
wash
twice
deionis
water
includ
soak
min
follow
three
wash
use
wash
buffer
tween
detect
captur
cytokin
correspond
biotinyl
detect
antibodi
ad
incub
h
rt
addit
three
wash
step
horseradish
peroxidas
hrp
ad
plate
incub
h
rt
final
four
wash
step
spot
develop
min
use
substrat
solut
l
aec
stock
solut
ml
mm
acet
solut
l
h
reaction
stop
wash
plate
deionis
water
dri
plate
h
rt
dark
spot
form
unit
sfu
count
use
autom
elispot
immunospot
analyz
ctleurop
gmbh
aalen
germani
analyz
use
ctl
immunospot
imag
analyz
softwar
result
express
sfu
spleen
cell
spot
produc
nonrestimul
cell
serv
background
subtract
spot
produc
restimul
cell
ratio
stimul
versu
nonstimul
spot
analyz
signific
differ
observ
immunogen
studi
analyz
use
student
unpair
ttest
nonparametr
mannwhitney
rank
sum
test
sigmastat
window
systat
softwar
inc
san
jose
usa
p
consid
signific
mvasarsnc
gener
insert
sarsnc
express
cassett
transfer
plasmid
direct
homolog
recombin
delet
site
iii
within
genom
mva
fig
pcr
analysi
viral
genom
confirm
genet
puriti
stabil
newli
gener
vaccin
strain
mvasarsnc
fig
expect
locu
result
pcr
product
bp
lane
comparison
bp
mva
wild
type
strain
lane
pcr
insert
site
delet
iii
reveal
fragment
bp
correspond
insert
sarsnc
lane
wherea
mva
wild
type
yield
product
bp
expect
empti
insert
site
lane
furthermor
correct
express
sarsnc
protein
assess
infect
chicken
embryo
fibroblast
cell
mvasarsnc
western
blot
analysi
fig
lysat
cell
infect
recombin
mva
specif
signal
kda
lane
correspond
nc
detect
wherea
mva
mock
infect
lead
signal
recombin
nc
clone
express
e
coli
ntermin
polyhistidin
tag
protein
see
materi
method
purif
use
imac
affin
column
refold
yield
high
amount
solubl
pure
protein
detect
degrad
product
judg
sdspage
coomassieblu
stain
data
shown
proper
reactiv
antigen
immunoblot
assess
use
variou
polyclon
antinc
antisera
includ
also
sera
human
sar
patient
data
shown
immunogen
recombin
nc
test
immun
rabbit
result
antisera
detect
nc
specif
stimul
protect
antibodi
respons
essenti
order
effici
prevent
viral
infect
thu
analyz
immunogen
potenti
differ
vaccin
formul
differ
immun
protocol
vaccin
formul
tabl
well
toler
anim
show
alter
weight
food
intak
gener
behavior
furthermor
observ
obviou
patholog
modif
organ
lung
liver
spleen
vaccin
anim
data
shown
high
titer
ncspecif
antibodi
stimul
intramuscular
immun
nc
protein
coadminist
alum
day
similar
igg
respons
observ
follow
protocol
mice
prime
nc
plu
alum
day
follow
heterolog
boost
mvanc
intramuscular
rout
day
fig
contrast
anim
vaccin
intranas
rout
show
poor
igg
respons
signific
increment
ncspecif
antibodi
titer
observ
group
mice
prime
nc
coadminist
intranas
rout
follow
heterolog
intramuscular
boost
mvanc
fig
interestingli
intramuscular
immun
mice
nc
coadminist
alum
elicit
immun
respons
indic
domin
isotyp
mix
respons
stimul
boost
mvanc
fig
furthermor
immun
anim
intranas
rout
nc
coadminist
follow
intramuscular
inject
mvanc
respons
stimul
indic
increas
isotyp
fig
evalu
elicit
mucos
respons
vaccin
anim
signific
p
increas
level
ncspecif
secretori
iga
siga
detect
bronchoalveolar
lavag
mice
vaccin
twice
nc
coadminist
prime
nc
boost
mvanc
fig
siga
detect
mice
immun
parenter
rout
data
shown
follow
immun
parenter
rout
strongest
cellular
respons
obtain
prime
nc
admix
alum
follow
booster
inject
mvanc
fig
p
hand
compar
group
mice
immun
intranas
rout
strongest
prolif
respons
observ
anim
receiv
two
time
nc
protein
coadminist
fig
howev
intranas
vaccin
singl
dose
nc
protein
coadminist
also
stimul
strong
cellular
respons
boost
mvanc
intramuscular
rout
fig
observ
result
statist
signific
respect
valu
mice
receiv
nc
protein
alon
p
signific
differ
observ
compar
group
receiv
nc
alon
control
group
receiv
pb
mva
fig
investig
cytokin
produc
splenocyt
vaccin
anim
number
cell
significantli
increas
anim
receiv
primeboost
protocol
fig
highest
number
detect
mice
prime
recombin
nc
protein
alum
boost
mvanc
intramuscular
rout
follow
prime
nc
protein
intranas
rout
boost
mvanc
interestingli
differ
observ
anim
receiv
empti
mva
receiv
two
dose
mvanc
intramuscular
rout
hand
intranas
immun
nc
coadminist
follow
either
homolog
heterolog
ie
mvanc
boost
result
signific
increment
number
secret
cell
ie
homolog
boost
p
heterolog
boost
p
fig
lesser
extent
secret
cell
also
increas
mice
receiv
system
primeboost
protocol
final
homolog
parenter
immun
nc
admix
alum
effici
regim
enhanc
product
p
compar
control
group
follow
heterolog
homolog
primeboost
mucos
vaccin
protocol
fig
major
experiment
vaccin
recent
develop
sarscov
aim
initi
steril
immun
via
viru
neutral
antibodi
includ
use
inactiv
sar
viru
protein
well
differ
deliveri
system
thereof
dna
viral
vector
adenoviru
rabi
parainfluenza
mvavaccinia
anim
trial
demonstr
potenti
protein
promot
induct
neutral
antibodi
case
also
protect
viral
challeng
sever
immun
studi
also
perform
nc
protein
sarscov
appli
protein
dna
viral
vector
eg
adenoviru
mva
good
immunogen
nc
antigen
could
shown
induct
antibodi
andor
tcell
respons
work
perform
sidebysid
comparison
differ
strategi
optim
immun
respons
nc
protein
sarscov
live
attenu
mva
vector
use
protein
deliveri
achiev
good
long
last
system
local
tcell
respons
induct
humor
immun
respons
recombin
nc
protein
coadminist
system
mucos
adjuv
differ
rout
intramuscular
intranas
special
attempt
also
carri
finetun
broaden
elicit
respons
combin
differ
candid
primeboost
vaccin
protocol
inclus
mvanc
heterolog
primeboost
protocol
base
wellknown
capac
recombin
mva
boost
cellular
respons
previous
prime
host
primeboost
regimen
use
differ
viral
vector
express
recombin
antigen
prove
effici
enhanc
target
antigen
specif
immun
respons
comparison
homolog
vector
immun
like
approach
circumv
problem
antivector
immun
context
prime
nc
protein
coadminist
mucos
adjuv
follow
boost
mvanc
appeal
promis
approach
promot
humor
cell
mediat
respons
nc
would
expect
lead
better
control
viral
infect
mucos
system
level
intramuscular
immun
mice
nc
protein
admix
alum
stimul
strong
humor
immun
respons
signific
differ
convent
twice
nc
protein
alum
primeboost
nc
protein
alum
prime
mvanc
boost
protocol
tabl
howev
mice
receiv
primeboost
protocol
helper
respons
pattern
switch
domin
mix
respect
anim
vaccin
nc
alum
alon
contrast
observ
humor
level
significantli
stronger
prolif
respons
comparison
control
mice
receiv
mva
alon
p
observ
anim
receiv
primeboost
protocol
true
term
observ
increment
number
produc
cell
henc
mvabas
boost
critic
modul
elicit
immun
respons
toward
mix
respons
pattern
well
optim
cellular
respons
nevertheless
vaccin
parenter
rout
abl
induc
relev
amount
antibodi
respiratori
tract
hand
immun
intranas
rout
although
overal
respons
slightli
weaker
serum
igg
respons
observ
anim
receiv
either
homolog
nc
protein
base
heterolog
nc
protein
intranas
prime
mvanc
intramuscular
base
vaccin
protocol
protocol
also
proven
effect
term
stimul
local
product
ncspecif
siga
bronchoalveolar
lavag
vaccin
mice
p
interestingli
vaccin
protocol
even
effect
parenter
primeboost
protocol
term
stimul
prolif
respons
p
strongest
respons
mice
vaccin
twice
nc
howev
analyz
cytokin
product
splenocyt
immun
mice
signific
increment
number
produc
cell
observ
mice
receiv
heterolog
primeboost
protocol
respect
control
group
p
furthermor
highest
increment
number
cell
respons
antigen
stimul
detect
mice
receiv
mucos
formul
follow
receiv
parenter
heterolog
primeboost
protocol
p
expect
product
maxim
mice
immun
nc
protein
alum
intramuscular
rout
p
thu
data
demonstr
heterolog
prime
boost
protocol
base
intranas
prime
nc
intramuscular
boost
mvanc
abl
induc
good
humor
cellular
immun
respons
system
mucos
level
strength
observ
immun
respons
similar
even
better
report
former
studi
eg
use
dnaor
adenovirusbas
approach
alon
furthermor
experi
indic
one
mvanc
boost
enough
stimul
singl
nc
protein
prime
clearli
superior
homolog
mvanc
primeboost
gener
consensu
vaccin
mucos
rout
offer
sever
advantag
parenter
immun
sinc
mucos
vaccin
promot
immun
respons
system
mucos
level
wherea
parenter
immun
stimul
system
respons
recent
shown
fatal
sar
case
predominantli
alveolar
pneumocyt
infect
demonstr
detect
sarscov
nucleoprotein
thu
stimul
effici
local
immun
respons
portal
entri
highli
desir
pathogen
like
sarscov
fact
strategi
lead
protect
diseas
also
infect
ie
colon
therebi
contribut
reduc
risk
horizont
transmiss
although
stimul
proteinspecif
antibodi
respons
seem
essenti
order
protect
sar
infect
possibl
antibodydepend
enhanc
exacerb
diseas
turn
underlin
need
altern
vaccin
use
nc
protein
altern
vaccin
approach
may
also
becom
attract
fact
nucleoprotein
differ
anim
coronavirus
share
antigen
crossreact
may
interest
vaccin
human
viru
anim
origin
present
studi
show
approach
character
mucos
prime
protein
system
boost
mvanc
superior
either
homolog
mucos
parenter
regimen
one
induc
serum
antibodi
lung
siga
cellular
respons
usual
product
cytokin
associ
cellmedi
immun
resist
intracellular
pathogen
dramat
increas
sarscov
infect
wherea
domin
cytokin
promot
humor
immun
protect
extra
cellular
microbi
infect
decreas
onset
sarscov
infect
also
upregul
proinflammatori
cytokin
tumor
necrosi
factor
alpha
might
enhanc
diseas
outcom
thu
stimul
domin
respons
increas
number
produc
cell
mucosalsystem
proteinmvabas
primeboost
protocol
appeal
addit
advantag
promis
vaccin
approach
